CardioTeca CardioTeca CardioTeca CardioTeca
Nuevo Abrimos Salud Cardiovascular, el espacio de CardioTeca para tus pacientes, con más de 400 artículos firmados por profesionales.Abrimos Salud Cardiovascular, para tus pacientes → Verlo →
Para tus pacientes
ESPACIO Diabetes cardiovascular

Biblioteca de referencias

Detalles
G
ESPACIO de diabetes › Bloque G › G4

Guías y evidencia

Lo que recomiendan las guías y lo que demuestran los estudios, separando siempre lo aprobado de lo que se investiga.

G4

Todas las fuentes citadas en el ESPACIO, en formato Vancouver, con DOI y PMID verificados, filtrables por tema y descargables para un gestor bibliográfico.

La evidencia en el tiempo: los artículos y guías citados en este ESPACIO, por año (1 anteriores a 1990, fuera del eje)

5101520253012422222454335545101712181516171928202219901995200020052010201520202025
296referencias: 250 artículos y guías, comprobados en PubMed y Crossref, y 46 fichas técnicas70de 2024, 2025 y 202649guías, consensos y declaraciones científicas

La lista se hace sola con lo que citan las páginas de este ESPACIO y se descarga en RIS.

Descargar en RIS (296 referencias)

Artículos y guías en PubMed (247)

  1. ACCORD Study Group, Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1575-85. doi:10.1056/NEJMoa1001286 · PMID 20228401C8
  2. Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-59. doi:10.1056/NEJMoa0802743 · PMID 18539917G2
  3. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B, Billot L, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560-72. doi:10.1056/NEJMoa0802987 · PMID 18539916C5G2I1
  4. Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43(6):474-484. doi:10.1093/eurheartj/ehab777 · PMID 35023547C5C10G2I1
  5. Agarwal R, Green JB, Heerspink HJL, Mann JFE, McGill JB, Mottl AK, et al. Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes. N Engl J Med. 2025;393(6):533-543. doi:10.1056/NEJMoa2410659 · PMID 40470996C5C7C10G2G5I1
  6. Ajjan RA, Heller SR, Everett CC, Vargas-Palacios A, Higham R, Sharples L, et al. Multicenter Randomized Trial of Intermittently Scanned Continuous Glucose Monitoring Versus Self-Monitoring of Blood Glucose in Individuals With Type 2 Diabetes and Recent-Onset Acute Myocardial Infarction: Results of the LIBERATES Trial. Diabetes Care. 2023;46(2):441-449. doi:10.2337/dc22-1219 · PMID 36516054C9
  7. American Diabetes Association Professional Practice Committee for Diabetes. 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes-2026. Diabetes Care. 2026;49(Suppl 1):S216-S245. doi:10.2337/dc26-S010 · PMID 41358899B4B6C4C6C8G1I1
  8. American Diabetes Association Professional Practice Committee for Diabetes. 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2026. Diabetes Care. 2026;49(Suppl 1):S246-S260. doi:10.2337/dc26-S011 · PMID 41358881B4C10
  9. American Diabetes Association Professional Practice Committee for Diabetes. 16. Diabetes Care in the Hospital: Standards of Care in Diabetes-2026. Diabetes Care. 2026;49(Supplement_1):S339-S355. doi:10.2337/dc26-S016 · PMID 41358892C9G1I1
  10. American Diabetes Association Professional Practice Committee for Diabetes. 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026. Diabetes Care. 2026;49(Supplement_1):S132-S149. doi:10.2337/dc26-S006 · PMID 41358894D4H5
  11. American Diabetes Association Professional Practice Committee for Diabetes. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026. Diabetes Care. 2026;49(Suppl 1):S183-S215. doi:10.2337/dc26-S009 · PMID 41358900C4G1I1
  12. American Diabetes Association Professional Practice Committee for Diabetes. Summary of Revisions: Standards of Care in Diabetes-2026. Diabetes Care. 2026;49(1 Suppl 1):S6-S12. doi:10.2337/dc26-SREV · PMID 41358896G1
  13. Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021;385(16):1451-1461. doi:10.1056/NEJMoa2107038 · PMID 34449189C7I1
  14. Anselmino M, Bartnik M, Malmberg K, Rydén L, Euro Heart Survey Investigators. Management of coronary artery disease in patients with and without diabetes mellitus. Acute management reasonable but secondary prevention unacceptably poor: a report from the Euro Heart Survey on Diabetes and the Heart. Eur J Cardiovasc Prev Rehabil. 2007;14(1):28-36. doi:10.1097/01.hjr.0000199496.23838.83 · PMID 17301624G3
  15. Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373(9678):1849-60. doi:10.1016/S0140-6736(09)60503-1 · PMID 19482214C8
  16. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation. 2004;110(5):588-636. doi:10.1161/01.CIR.0000134791.68010.FA · PMID 15289388B6H4
  17. Aronne LJ, Sattar N, Horn DB, Bays HE, Wharton S, Lin WY, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48. doi:10.1001/jama.2023.24945 · PMID 38078870H3
  18. ASCEND Study Collaborative Group, Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, et al. Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus. N Engl J Med. 2018;379(16):1529-1539. doi:10.1056/NEJMoa1804988 · PMID 30146931C8G2H1
  19. Assogba GF, Couchoud C, Roudier C, Pornet C, Fosse S, Romon I, et al. Prevalence, screening and treatment of chronic kidney disease in people with type 2 diabetes in France: the ENTRED surveys (2001 and 2007). Diabetes Metab. 2012;38(6):558-66. doi:10.1016/j.diabet.2012.08.004 · PMID 23036461G3
  20. Authors/Task Force Members, Rydén L, Grant PJ, Anker SD, Berne C, Cosentino F, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J. 2013;34(39):3035-87. doi:10.1093/eurheartj/eht108 · PMID 23996285G1
  21. Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020;383(23):2219-2229. doi:10.1056/NEJMoa2025845 · PMID 33264825C5C7C10G2I1
  22. BARI 2D Study Group, Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360(24):2503-15. doi:10.1056/NEJMoa0805796 · PMID 19502645C9G2
  23. Bartnik M, Rydén L, Malmberg K, Ohrvik J, Pyörälä K, Standl E, et al. Oral glucose tolerance test is needed for appropriate classification of glucose regulation in patients with coronary artery disease: a report from the Euro Heart Survey on Diabetes and the Heart. Heart. 2007;93(1):72-7. doi:10.1136/hrt.2005.086975 · PMID 16905628G3
  24. Baudry G, Biegus J, López-Azor JC, Bozkurt B, Butler J, Cobo-Marcos M, et al. Redefining Cardiometabolic Disease: Expert Consensus on the CardioVascular-Kidney-Liver-Metabolic (CVKLM) Multiorgan Staging. Eur J Prev Cardiol. 2026. doi:10.1093/eurjpc/zwag563 · PMID 42945405C7H3
  25. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002;287(19):2570-81. doi:10.1001/jama.287.19.2570 · PMID 12020339H1
  26. Bhatt DL, Cryer BL, Contant CF, Cohen M, Lanas A, Schnitzer TJ, et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363(20):1909-17. doi:10.1056/NEJMoa1007964 · PMID 20925534C8
  27. Bhatt DL, Bonaca MP, Bansilal S, Angiolillo DJ, Cohen M, Storey RF, et al. Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS-TIMI 54. J Am Coll Cardiol. 2016;67(23):2732-2740. doi:10.1016/j.jacc.2016.03.529 · PMID 27046160C8
  28. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380(1):11-22. doi:10.1056/NEJMoa1812792 · PMID 30415628C8
  29. Bhatt DL, Eikelboom JW, Connolly SJ, Steg PG, Anand SS, Verma S, et al. Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial. Circulation. 2020;141(23):1841-1854. doi:10.1161/CIRCULATIONAHA.120.046448 · PMID 32223318C8
  30. Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. N Engl J Med. 2021;384(2):129-139. doi:10.1056/NEJMoa2030186 · PMID 33200891C5G2
  31. Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. N Engl J Med. 2021;384(2):117-128. doi:10.1056/NEJMoa2030183 · PMID 33200892C5G2
  32. Bi Y, Li M, Liu Y, Li T, Lu J, Duan P, et al. Intensive Blood-Pressure Control in Patients with Type 2 Diabetes. N Engl J Med. 2025;392(12):1155-1167. doi:10.1056/NEJMoa2412006 · PMID 39555827C8
  33. Blin P, Joubert M, Jourdain P, Zaoui P, Guiard E, Sakr D, et al. Cardiovascular and renal diseases in type 2 diabetes patients: 5-year cumulative incidence of the first occurred manifestation and hospitalization cost: a cohort within the French SNDS nationwide claims database. Cardiovasc Diabetol. 2024;23(1):22. doi:10.1186/s12933-023-02101-1 · PMID 38195491G3
  34. Bonaca MP, Catarig AM, Houlind K, Ludvik B, Nordanstig J, Ramesh CK, et al. Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial. Lancet. 2025;405(10489):1580-1593. doi:10.1016/S0140-6736(25)00509-4 · PMID 40169145C5G2G5I1
  35. Bravo Baptista S, Pires de Morais G, Almeida Morais L, Costa J, Vinhas H, Campos G, et al. Anti-thrombotic and glucose lowering therapy in diabetic patients with coronary artery disease undergoing PCI with stent implantation: A prospective multicenter observational study on prescription patterns and clinical outcomes. Baseline inclusion data of the ARTHEMIS registry. Rev Port Cardiol. 2025;44(9):537-546. doi:10.1016/j.repc.2025.03.006 · PMID 40738464G3
  36. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861-9. doi:10.1056/NEJMoa011161 · PMID 11565518C10G2
  37. Butler J, Jones WS, Udell JA, Anker SD, Petrie MC, Harrington J, et al. Empagliflozin after Acute Myocardial Infarction. N Engl J Med. 2024;390(16):1455-1466. doi:10.1056/NEJMoa2314051 · PMID 38587237C4C5G2
  38. Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720-3826. doi:10.1093/eurheartj/ehad191 · PMID 37622654B1B6C4C6C9D1E3G1H4
  39. Bäck M, Wilhelm M, Marcin T, Machado FVC, Sandberg A, Buccheri S, et al. 2026 ESC Guidelines on cardiac rehabilitation. Eur Heart J. 2026;47(39):5631-5729. doi:10.1093/eurheartj/ehag099 · PMID 42661418B4C6C8D1D4G1H3
  40. Cai X, Zhang Y, Li M, Wu JH, Mai L, Li J, et al. Association between prediabetes and risk of all cause mortality and cardiovascular disease: updated meta-analysis. BMJ. 2020;370:m2297. doi:10.1136/bmj.m2297 · PMID 32669282C7H3
  41. Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U, et al. Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. N Engl J Med. 2020;383(15):1425-1435. doi:10.1056/NEJMoa2004967 · PMID 32966714C5G2I1
  42. Carrasco-Sánchez FJ, Fernández-Rodríguez JM, Ena J, Gómez-Huelgas R, Carretero-Gómez J, en representación del Grupo de trabajo de Diabetes, Obesidad y Nutrición de la Sociedad Española de Medicina Interna. Medical treatment of type 2 diabetes mellitus: Recommendations of the Diabetes, Obesity and Nutrition Group of the Spanish Society of Internal Medicine. Rev Clin Esp. 2021;221(2):101-108. doi:10.1016/j.rce.2020.06.005 · PMID 32674850G1
  43. Carrasco-Sánchez FJ, Páez-Rubio MI, Arévalo-Lorido JC, Carretero-Gómez J, Conde-Martel A, Epelde F, et al. Changes over time in the association between type 2 diabetes and post-discharge outcomes in decompensated chronic heart failure patients: Findings from the RICA Registry. Rev Clin Esp (Barc). 2022;222(2):63-72. doi:10.1016/j.rceng.2021.04.010 · PMID 34629306G3
  44. Cascales Guerrero G, Chicharro-Luna E, Cordero A, Barber-Valles X, Flores Pardo E, Salinas Serrano JM, et al. Diabetes, Long-term mortality, and LDL-C target attainment after an acute coronary syndrome: A population-based cohort study (2016-2024). Diabetes Res Clin Pract. 2026;242:113602. doi:10.1016/j.diabres.2026.113602 · PMID 42880667G3
  45. Castro Conde A, Marzal Martín D, Campuzano Ruiz R, Fernández Olmo MR, Morillas Ariño C, Gómez Doblas JJ, et al. Comprehensive Cardiovascular and Renal Protection in Patients with Type 2 Diabetes. J Clin Med. 2023;12(12). doi:10.3390/jcm12123925 · PMID 37373620G1
  46. Cebrián Cuenca A, Cornejo Martin J, Álvarez Guisasola F, Orozco Beltrán D, Quesada JA, Artola Menéndez S, et al. Undiagnosed chronic kidney disease in people with type 2 diabetes in Spain: Prevalence, treatment patterns and associated factors in a multicentre cross-sectional study. Prim Care Diabetes. 2026;20(3):298-305. doi:10.1016/j.pcd.2026.02.007 · PMID 41741270G3
  47. Cholesterol Treatment Trialists' (CTT) Collaborators, Kearney PM, Blackwell L, Collins R, Keech A, Simes J, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet. 2008;371(9607):117-25. doi:10.1016/S0140-6736(08)60104-X · PMID 18191683C8
  48. Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375(9731):2073-81. doi:10.1016/S0140-6736(10)60674-5 · PMID 20483451H1
  49. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364(9435):685-96. doi:10.1016/S0140-6736(04)16895-5 · PMID 15325833C8
  50. Control Group, Turnbull FM, Abraira C, Anderson RJ, Byington RP, Chalmers JP, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia. 2009;52(11):2288-98. doi:10.1007/s00125-009-1470-0 · PMID 19655124H1
  51. Correction to: 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC). Eur Heart J. 2023;44(48):5060. doi:10.1093/eurheartj/ehad774 · PMID 37989571G1
  52. Correction to: 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC). Eur Heart J. 2024;45(7):518. doi:10.1093/eurheartj/ehad857 · PMID 38247449G1
  53. Correction to: 2026 ESC Guidelines for the management of cardiovascular disease and chronic kidney disease, in collaboration with the European Renal Association (ERA): Developed by the task force on the management of cardiovascular disease and chronic kidney disease of the European Society of Cardiology (ESC). Eur Heart J. 2026. doi:10.1093/eurheartj/ehag884 · PMID 42927774B4B6C8C10G1
  54. Correction to: 2026 ESC Guidelines on cardiac rehabilitation: Developed by the task force on cardiac rehabilitation of the European Society of Cardiology (ESC)Endorsed by the European Society of Physical and Rehabilitation Medicine (ESPRM) and World Organization of Family Doctors (WONCA). Eur Heart J. 2026. doi:10.1093/eurheartj/ehag887 · PMID 42921976G1
  55. Corrigendum to: 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(45):4317. doi:10.1093/eurheartj/ehz828 · PMID 31837138G1
  56. Cosentino F, Cannon CP, Cherney DZI, Masiukiewicz U, Pratley R, Dagogo-Jack S, et al. Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial. Circulation. 2020;142(23):2205-2215. doi:10.1161/CIRCULATIONAHA.120.050255 · PMID 33026243C5G2I1
  57. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255-323. doi:10.1093/eurheartj/ehz486 · PMID 31497854G1
  58. Damman K, Ter Maaten JM, Mayne KJ, Bolignano D, Brown EM, da Costa BR, et al. 2026 ESC Guidelines for the management of cardiovascular disease and chronic kidney disease, in collaboration with the European Renal Association (ERA). Eur Heart J. 2026. doi:10.1093/eurheartj/ehag098 · PMID 42661426B4B6C2C3C4C5C7C8C10D1D3D4E3G1H1H4H5I1
  59. Dauriz M, Targher G, Laroche C, Temporelli PL, Ferrari R, Anker S, et al. Association Between Diabetes and 1-Year Adverse Clinical Outcomes in a Multinational Cohort of Ambulatory Patients With Chronic Heart Failure: Results From the ESC-HFA Heart Failure Long-Term Registry. Diabetes Care. 2017;40(5):671-678. doi:10.2337/dc16-2016 · PMID 28255009G3
  60. Davies MJ, Bain SC, Atkin SL, Rossing P, Scott D, Shamkhalova MS, et al. Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial. Diabetes Care. 2016;39(2):222-30. doi:10.2337/dc14-2883 · PMID 26681713I1
  61. Davies MJ, Aroda VR, Collins BS, Gabbay RA, Green J, Maruthur NM, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022;45(11):2753-2786. doi:10.2337/dci22-0034 · PMID 36148880G1
  62. Davies MJ, Aroda VR, Bajaj M, ElSayed NA, Giorgino F, Green J, et al. Correction: Management of type 2 diabetes, 2026. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2026. doi:10.1007/s00125-026-06911-2 · PMID 42955083G1
  63. Davies MJ, Aroda VR, Bajaj M, ElSayed NA, Giorgino F, Green J, et al. Management of type 2 diabetes, 2026. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2026. doi:10.1007/s00125-026-06855-7 · PMID 42825923C4C6C7G1I1
  64. De Backer J, Haugaa KH, Hasselberg NE, de Hosson M, Brida M, Castelletti S, et al. 2025 ESC Guidelines for the management of cardiovascular disease and pregnancy. Eur Heart J. 2025;46(43):4462-4568. doi:10.1093/eurheartj/ehaf193 · PMID 40878294C6D1G1I1
  65. de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM, et al. Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022;45(12):3075-3090. doi:10.2337/dci22-0027 · PMID 36189689G1
  66. de-Miguel-Yanes JM, Jimenez-Garcia R, Hernandez-Barrera V, de-Miguel-Diez J, Jimenez-Sierra A, Zamorano-León JJ, et al. An observational study of therapeutic procedures and in-hospital outcomes among patients admitted for acute myocardial infarction in Spain, 2016-2022: the role of diabetes mellitus. Cardiovasc Diabetol. 2024;23(1):313. doi:10.1186/s12933-024-02403-y · PMID 39182091H2
  67. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia. 1989;32(4):219-26. doi:10.1007/BF00285287 · PMID 2668076H1
  68. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366(9493):1279-89. doi:10.1016/S0140-6736(05)67528-9 · PMID 16214598C5G2I1
  69. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129-39. doi:10.1056/NEJMoa0808431 · PMID 19092145G2
  70. Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med. 2017;377(14):1319-1330. doi:10.1056/NEJMoa1709118 · PMID 28844192C8
  71. Erdmann E, Charbonnel B, Wilcox RG, Skene AM, Massi-Benedetti M, Yates J, et al. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive study (PROactive 08). Diabetes Care. 2007;30(11):2773-8. doi:10.2337/dc07-0717 · PMID 17666462C5G2I1
  72. Estruch R, Ros E, Salas-Salvadó J, Covas MI, Corella D, Arós F, et al. Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. N Engl J Med. 2018;378(25):e34. doi:10.1056/NEJMoa1800389 · PMID 29897866C8
  73. Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, et al. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med. 2012;367(25):2375-84. doi:10.1056/NEJMoa1211585 · PMID 23121323C9G2
  74. Farkouh ME, Domanski M, Dangas GD, Godoy LC, Mack MJ, Siami FS, et al. Long-Term Survival Following Multivessel Revascularization in Patients With Diabetes: The FREEDOM Follow-On Study. J Am Coll Cardiol. 2019;73(6):629-638. doi:10.1016/j.jacc.2018.11.001 · PMID 30428398C9G2
  75. Ferrannini G, De Bacquer D, De Backer G, Kotseva K, Mellbin L, Wood D, et al. Screening for Glucose Perturbations and Risk Factor Management in Dysglycemic Patients With Coronary Artery Disease-A Persistent Challenge in Need of Substantial Improvement: A Report From ESC EORP EUROASPIRE V. Diabetes Care. 2020;43(4):726-733. doi:10.2337/dc19-2165 · PMID 32079627G3
  76. Ferrannini G, Tuomilehto J, De Backer G, Kotseva K, Mellbin L, Schnell O, et al. Dysglycaemia screening and its prognostic impact in patients with coronary artery disease: experiences from the EUROASPIRE IV and V cohort studies. Lancet Diabetes Endocrinol. 2024;12(11):790-798. doi:10.1016/S2213-8587(24)00201-8 · PMID 39326426G3
  77. Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515. doi:10.1056/NEJMoa2107519 · PMID 34170647I1
  78. Fu EL, Patorno E, Everett BM, Vaduganathan M, Solomon SD, Levin R, et al. Sodium-glucose cotransporter 2 inhibitors vs. sitagliptin in heart failure and type 2 diabetes: an observational cohort study. Eur Heart J. 2023;44(24):2216-2230. doi:10.1093/eurheartj/ehad273 · PMID 37259575G3
  79. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348(5):383-93. doi:10.1056/NEJMoa021778 · PMID 12556541C8
  80. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358(6):580-91. doi:10.1056/NEJMoa0706245 · PMID 18256393C8
  81. Garvey WT, Frias JP, Jastreboff AM, le Roux CW, Sattar N, Aizenberg D, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402(10402):613-626. doi:10.1016/S0140-6736(23)01200-X · PMID 37385275I1
  82. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286(4):421-6. doi:10.1001/jama.286.4.421 · PMID 11466120H1
  83. Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121-130. doi:10.1016/S0140-6736(19)31149-3 · PMID 31189511C5C7G2I1
  84. Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet. 2019;394(10193):131-138. doi:10.1016/S0140-6736(19)31150-X · PMID 31189509C5G2I1
  85. Gerstein HC, Sattar N, Rosenstock J, Ramasundarahettige C, Pratley R, Lopes RD, et al. Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes. N Engl J Med. 2021;385(10):896-907. doi:10.1056/NEJMoa2108269 · PMID 34215025C5G2
  86. Gil-Millan P, Gimeno-Orna JA, Rodriguez-Padial L, Muniz J, Barrios V, Anguita M, et al. HFpEF as the predominant and underrecognized heart failure phenotype in type 2 diabetes: evidence from the DIABET-IC study. Cardiovasc Diabetol. 2025;24(1):419. doi:10.1186/s12933-025-02995-z · PMID 41185008G3
  87. Giugliano RP, Cannon CP, Blazing MA, Nicolau JC, Corbalán R, Špinar J, et al. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation. 2018;137(15):1571-1582. doi:10.1161/CIRCULATIONAHA.117.030950 · PMID 29263150C8
  88. Goldberg RB, Orchard TJ, Crandall JP, Boyko EJ, Budoff M, Dabelea D, et al. Effects of Long-term Metformin and Lifestyle Interventions on Cardiovascular Events in the Diabetes Prevention Program and Its Outcome Study. Circulation. 2022;145(22):1632-1641. doi:10.1161/CIRCULATIONAHA.121.056756 · PMID 35603600C7H3
  89. Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation. 2006;114(6):597-605. doi:10.1161/CIRCULATIONAHA.106.621854 · PMID 16894049H1
  90. Gong Q, Zhang P, Wang J, Ma J, An Y, Chen Y, et al. Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study. Lancet Diabetes Endocrinol. 2019;7(6):452-461. doi:10.1016/S2213-8587(19)30093-2 · PMID 31036503C7H3
  91. Gonzalez-Manzanares R, Anguita-Gámez M, Muñiz J, Barrios V, Gimeno-Orna JA, Pérez A, et al. Prevalence and incidence of heart failure in type 2 diabetes patients: results from a nationwide prospective cohort-the DIABET-IC study. Cardiovasc Diabetol. 2024;23(1):253. doi:10.1186/s12933-024-02358-0 · PMID 39014420G3
  92. GRADE Study Research Group, Nathan DM, Lachin JM, Balasubramanyam A, Burch HB, Buse JB, et al. Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes. N Engl J Med. 2022;387(12):1063-1074. doi:10.1056/NEJMoa2200433 · PMID 36129996I1
  93. GRADE Study Research Group, Nathan DM, Lachin JM, Bebu I, Burch HB, Buse JB, et al. Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes. N Engl J Med. 2022;387(12):1075-1088. doi:10.1056/NEJMoa2200436 · PMID 36129997I1
  94. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2015;373(3):232-42. doi:10.1056/NEJMoa1501352 · PMID 26052984C5G2H5I1
  95. Gæde P, Oellgaard J, Carstensen B, Rossing P, Lund-Andersen H, Parving HH, et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia. 2016;59(11):2298-2307. doi:10.1007/s00125-016-4065-6 · PMID 27531506C8
  96. Halvorsen S, Mehilli J, Cassese S, Hall TS, Abdelhamid M, Barbato E, et al. 2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery. Eur Heart J. 2022;43(39):3826-3924. doi:10.1093/eurheartj/ehac270 · PMID 36017553C7C9D1D3E3G1I1
  97. Head SJ, Milojevic M, Daemen J, Ahn JM, Boersma E, Christiansen EH, et al. Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data. Lancet. 2018;391(10124):939-948. doi:10.1016/S0140-6736(18)30423-9 · PMID 29478841C9
  98. Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. Circulation. 2016;134(10):752-72. doi:10.1161/CIRCULATIONAHA.116.021887 · PMID 27470878H1H5
  99. Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436-1446. doi:10.1056/NEJMoa2024816 · PMID 32970396C5C7C10G2I1
  100. Heerspink HJL, Birkenfeld AL, Cherney DZI, Colhoun HM, Groop PH, Ji L, et al. Finerenone in Type 1 Diabetes and Chronic Kidney Disease. N Engl J Med. 2026;394(10):947-957. doi:10.1056/NEJMoa2512854 · PMID 41780000C10G2G5I1
  101. Hernandez AF, Green JB, Janmohamed S, D'Agostino RB Sr, Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519-1529. doi:10.1016/S0140-6736(18)32261-X · PMID 30291013C5G2
  102. Hirshberg B, Raz I. Impact of the U.S. Food and Drug Administration cardiovascular assessment requirements on the development of novel antidiabetes drugs. Diabetes Care. 2011;34 Suppl 2(Suppl 2):S101-6. doi:10.2337/dc11-s202 · PMID 21525438H5
  103. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577-89. doi:10.1056/NEJMoa0806470 · PMID 18784090H1
  104. Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, et al. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2017;377(13):1228-1239. doi:10.1056/NEJMoa1612917 · PMID 28910237C5G2
  105. Htoo PT, Tesfaye H, Schneeweiss S, Wexler DJ, Everett BM, Glynn RJ, et al. Effectiveness and safety of empagliflozin: final results from the EMPRISE study. Diabetologia. 2024;67(7):1328-1342. doi:10.1007/s00125-024-06126-3 · PMID 38509341G3
  106. Huang Y, Cai X, Mai W, Li M, Hu Y. Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta-analysis. BMJ. 2016;355:i5953. doi:10.1136/bmj.i5953 · PMID 27881363H3
  107. Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2019;381(9):841-851. doi:10.1056/NEJMoa1901118 · PMID 31185157C5C7G2H5I1
  108. Iacobellis G. Epicardial adipose tissue in contemporary cardiology. Nat Rev Cardiol. 2022;19(9):593-606. doi:10.1038/s41569-022-00679-9 · PMID 35296869H1
  109. International Hypoglycaemia Study Group. Glucose Concentrations of Less Than 3.0 mmol/L (54 mg/dL) Should Be Reported in Clinical Trials: A Joint Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2017;40(1):155-157. doi:10.2337/dc16-2215 · PMID 27872155H5
  110. James S, Erlinge D, Storey RF, McGuire DK, de Belder M, Eriksson N, et al. Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure. NEJM Evid. 2024;3(2):EVIDoa2300286. doi:10.1056/EVIDoa2300286 · PMID 38320489C4C5G2
  111. Jastreboff AM, le Roux CW, Stefanski A, Aronne LJ, Halpern B, Wharton S, et al. Tirzepatide for Obesity Treatment and Diabetes Prevention. N Engl J Med. 2025;392(10):958-971. doi:10.1056/NEJMoa2410819 · PMID 39536238C7H3
  112. Jeppsson A, Rocca B, Hansson EC, Gudbjartsson T, James S, Kaski JC, et al. 2024 EACTS Guidelines on perioperative medication in adult cardiac surgery. Eur J Cardiothorac Surg. 2024;67(1). doi:10.1093/ejcts/ezae355 · PMID 39385505C9I1
  113. Jia G, Hill MA, Sowers JR. Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity. Circ Res. 2018;122(4):624-638. doi:10.1161/CIRCRESAHA.117.311586 · PMID 29449364H1
  114. Jiménez A, Vlacho B, Mata-Cases M, Real J, Mauricio D, Franch-Nadal J, et al. Sex and age significantly modulate cardiovascular disease presentation in type 2 diabetes: a large population-based cohort study. Front Endocrinol (Lausanne). 2024;15:1344007. doi:10.3389/fendo.2024.1344007 · PMID 38828412G3
  115. Jorsal A, Kistorp C, Holmager P, Tougaard RS, Nielsen R, Hänselmann A, et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail. 2017;19(1):69-77. doi:10.1002/ejhf.657 · PMID 27790809I1
  116. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117-S314. doi:10.1016/j.kint.2023.10.018 · PMID 38490803B4B6C7C10D1G1H5I1
  117. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022;102(5S):S1-S127. doi:10.1016/j.kint.2022.06.008 · PMID 36272764G1
  118. Kindel TL, Wang AY, Wadhwa A, Schulman AR, Sharaiha RZ, Kroh M, et al. Multi-society clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period. Surg Endosc. 2025;39(1):180-183. doi:10.1007/s00464-024-11263-2 · PMID 39370500C9
  119. Klein KR, Wysham C, Tuttle KR, Davies MJ, Cox D, Chen J, et al. Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial. Lancet. 2026;408(10564):1557-1570. doi:10.1016/S0140-6736(26)01865-9 · PMID 42815506C5C7G2G5H5
  120. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403. doi:10.1056/NEJMoa012512 · PMID 11832527C7H3
  121. Kosiborod M, Cavender MA, Fu AZ, Wilding JP, Khunti K, Holl RW, et al. Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors). Circulation. 2017;136(3):249-259. doi:10.1161/CIRCULATIONAHA.117.029190 · PMID 28522450G3
  122. Kosiborod M, Lam CSP, Kohsaka S, Kim DJ, Karasik A, Shaw J, et al. Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study. J Am Coll Cardiol. 2018;71(23):2628-2639. doi:10.1016/j.jacc.2018.03.009 · PMID 29540325G3
  123. Kosiborod MN, Deanfield J, Pratley R, Borlaug BA, Butler J, Davies MJ, et al. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials. Lancet. 2024;404(10456):949-961. doi:10.1016/S0140-6736(24)01643-X · PMID 39222642I1
  124. Kosiborod MN, Petrie MC, Borlaug BA, Butler J, Davies MJ, Hovingh GK, et al. Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes. N Engl J Med. 2024;390(15):1394-1407. doi:10.1056/NEJMoa2313917 · PMID 38587233C5G2G5I1
  125. Koskinas KC, Van Craenenbroeck EM, Antoniades C, Blüher M, Gorter TM, Hanssen H, et al. Obesity and cardiovascular disease: an ESC clinical consensus statement. Eur Heart J. 2024;45(38):4063-4098. doi:10.1093/eurheartj/ehae508 · PMID 39210706C7H1H3
  126. Køber L, Adamo M, Ruwald AC, Tomasoni D, Anderson LJ, Andersson C, et al. 2026 ESC Guidelines for the management of heart failure. Eur Heart J. 2026;47(38):5346-5457. doi:10.1093/eurheartj/ehag100 · PMID 42661420B1B6C2C4C5C6C7C8D1D3G1H1H3H4I1
  127. Laakso M, Kuusisto J. Insulin resistance and hyperglycaemia in cardiovascular disease development. Nat Rev Endocrinol. 2014;10(5):293-302. doi:10.1038/nrendo.2014.29 · PMID 24663222H1H5
  128. Lamperti M, Romero CS, Guarracino F, Cammarota G, Vetrugno L, Tufegdzic B, et al. Preoperative assessment of adults undergoing elective noncardiac surgery: Updated guidelines from the European Society of Anaesthesiology and Intensive Care. Eur J Anaesthesiol. 2025;42(1):1-35. doi:10.1097/EJA.0000000000002069 · PMID 39492705C9I1
  129. Lenzen M, Ryden L, Ohrvik J, Bartnik M, Malmberg K, Scholte Op Reimer W, et al. Diabetes known or newly detected, but not impaired glucose regulation, has a negative influence on 1-year outcome in patients with coronary artery disease: a report from the Euro Heart Survey on diabetes and the heart. Eur Heart J. 2006;27(24):2969-74. doi:10.1093/eurheartj/ehl363 · PMID 17090612G3
  130. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851-60. doi:10.1056/NEJMoa011303 · PMID 11565517C10G2
  131. Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563 · PMID 37952131C5C7G2H3I1
  132. Look AHEAD Research Group, Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145-54. doi:10.1056/NEJMoa1212914 · PMID 23796131G2H3
  133. Look AHEAD Research Group, Gregg EW, Jakicic JM, Blackburn G, Bloomquist P, Bray GA, et al. Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol. 2016;4(11):913-921. doi:10.1016/S2213-8587(16)30162-0 · PMID 27595918H3
  134. Lopaschuk GD, Verma S. Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review. JACC Basic Transl Sci. 2020;5(6):632-644. doi:10.1016/j.jacbts.2020.02.004 · PMID 32613148H1H5
  135. Lopez-de-Andres A, Jimenez-Garcia R, Hernández-Barrera V, de Miguel-Yanes JM, Albaladejo-Vicente R, Villanueva-Orbaiz R, et al. Are there sex differences in the effect of type 2 diabetes in the incidence and outcomes of myocardial infarction? A matched-pair analysis using hospital discharge data. Cardiovasc Diabetol. 2021;20(1):81. doi:10.1186/s12933-021-01273-y · PMID 33888124H2
  136. Lopez-de-Andres A, Jimenez-Garcia R, Carabantes-Alarcon D, Hernández-Barrera V, de-Miguel-Yanes JM, de-Miguel-Diez J, et al. Use of Cardiac Procedures in People with Diabetes during the COVID Pandemic in Spain: Effects on the In-Hospital Mortality. Int J Environ Res Public Health. 2023;20(1). doi:10.3390/ijerph20010844 · PMID 36613166H2
  137. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-188. doi:10.1093/eurheartj/ehz455 · PMID 31504418C6C8G1
  138. Mach F, Koskinas KC, Roeters van Lennep JE, Tokgözoğlu L, Badimon L, Baigent C, et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2025;46(42):4359-4378. doi:10.1093/eurheartj/ehaf190 · PMID 40878289B1G1
  139. Malmberg K, Rydén L, Efendic S, Herlitz J, Nicol P, Waldenström A, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol. 1995;26(1):57-65. doi:10.1016/0735-1097(95)00126-k · PMID 7797776C9
  140. Malmberg K, Rydén L, Wedel H, Birkeland K, Bootsma A, Dickstein K, et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J. 2005;26(7):650-61. doi:10.1093/eurheartj/ehi199 · PMID 15728645C9
  141. Margulies KB, Hernandez AF, Redfield MM, Givertz MM, Oliveira GH, Cole R, et al. Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. JAMA. 2016;316(5):500-8. doi:10.1001/jama.2016.10260 · PMID 27483064I1
  142. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375(19):1834-1844. doi:10.1056/NEJMoa1607141 · PMID 27633186C5C7G2H5I1
  143. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-22. doi:10.1056/NEJMoa1603827 · PMID 27295427C5C7G2I1
  144. Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, et al. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. N Engl J Med. 2017;377(8):723-732. doi:10.1056/NEJMoa1615692 · PMID 28605603C5G2I1
  145. Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043-4140. doi:10.1093/eurheartj/ehad192 · PMID 37622663B4B6C2C3C4C5C6C7C8C9C10D1D3D4E3G1G5H1H3H4H5I1
  146. Maser RE, Mitchell BD, Vinik AI, Freeman R. The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. Diabetes Care. 2003;26(6):1895-901. doi:10.2337/diacare.26.6.1895 · PMID 12766130H1H5
  147. Mata-Cases M, Vlacho B, Real J, Puig-Treserra R, Bundó M, Franch-Nadal J, et al. Trends in the Degree of Control and Treatment of Cardiovascular Risk Factors in People With Type 2 Diabetes in a Primary Care Setting in Catalonia During 2007-2018. Front Endocrinol (Lausanne). 2021;12:810757. doi:10.3389/fendo.2021.810757 · PMID 35082758G3
  148. Mazzolai L, Teixido-Tura G, Lanzi S, Boc V, Bossone E, Brodmann M, et al. 2024 ESC Guidelines for the management of peripheral arterial and aortic diseases. Eur Heart J. 2024;45(36):3538-3700. doi:10.1093/eurheartj/ehae179 · PMID 39210722B4C6C8E3G1I1
  149. McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912-4018. doi:10.1093/eurheartj/ehae178 · PMID 39210715B1B4C6C8D3G1H3
  150. McGuire DK, Alexander JH, Johansen OE, Perkovic V, Rosenstock J, Cooper ME, et al. Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA. Circulation. 2019;139(3):351-361. doi:10.1161/CIRCULATIONAHA.118.038352 · PMID 30586723I1
  151. McGuire DK, Marx N, Mulvagh SL, Deanfield JE, Inzucchi SE, Pop-Busui R, et al. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes. N Engl J Med. 2025;392(20):2001-2012. doi:10.1056/NEJMoa2501006 · PMID 40162642C5C7C10D1G2G5I1
  152. McMurray JJV, Ponikowski P, Bolli GB, Lukashevich V, Kozlovski P, Kothny W, et al. Effects of Vildagliptin on Ventricular Function in Patients With Type 2 Diabetes Mellitus and Heart Failure: A Randomized Placebo-Controlled Trial. JACC Heart Fail. 2018;6(1):8-17. doi:10.1016/j.jchf.2017.08.004 · PMID 29032139I1
  153. McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019;381(21):1995-2008. doi:10.1056/NEJMoa1911303 · PMID 31535829C7I1
  154. Mosenzon O, Alguwaihes A, Leon JLA, Bayram F, Darmon P, Davis TME, et al. CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries. Cardiovasc Diabetol. 2021;20(1):154. doi:10.1186/s12933-021-01344-0 · PMID 34315481G3
  155. Muñoz MA, Cendrós V, Navas E, Verdú-Rotellar JM, Barrot J, Franch J. Incidence of first hospitalization for heart failure in type 2 diabetes mellitus: A population-based cohort study in primary care. Prim Care Diabetes. 2025;19(5):471-477. doi:10.1016/j.pcd.2025.07.009 · PMID 40764218G3
  156. Muñoz-Rivas N, Jiménez-García R, Méndez-Bailón M, Hernández-Barrera V, de Miguel-Díez J, Lorenzo-Villalba N, et al. Type 2 diabetes increases the risk of hospital admission for heart failure and reduces the risk of in hospital mortality in Spain (2001-2015). Eur J Intern Med. 2019;59:53-59. doi:10.1016/j.ejim.2018.08.011 · PMID 30143395H2
  157. Méndez-Bailón M, Lorenzo-Villalba N, Jiménez-García R, Hernández-Barrera V, de Miguel-Yanes JM, de Miguel-Diez J, et al. Clinical Characteristics, Management, and In-Hospital Mortality in Patients with Heart Failure with Reduced Ejection Fraction According to Sex and the Presence of Type 2 Diabetes Mellitus. J Clin Med. 2022;11(4). doi:10.3390/jcm11041030 · PMID 35207300H2
  158. Navarro-Pérez J, Orozco-Beltran D, Gil-Guillen V, Pallares V, Valls F, Fernandez A, et al. Mortality and cardiovascular disease burden of uncontrolled diabetes in a registry-based cohort: the ESCARVAL-risk study. BMC Cardiovasc Disord. 2018;18(1):180. doi:10.1186/s12872-018-0914-1 · PMID 30176799G3
  159. Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS, et al. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. Circulation. 2023;148(20):1606-1635. doi:10.1161/CIR.0000000000001184 · PMID 37807924C7H3H5
  160. Ndumele CE, Rodriguez F, Dixon DL, Khan SS, Mukherjee D, Bajaj M, et al. 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2026;87(22S):e1889-e2007. doi:10.1016/j.jacc.2026.03.056 · PMID 42265997C7G1H3H5
  161. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(7):644-657. doi:10.1056/NEJMoa1611925 · PMID 28605608C5G2I1
  162. Neeland IJ, Ross R, Després JP, Matsuzawa Y, Yamashita S, Shai I, et al. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. Lancet Diabetes Endocrinol. 2019;7(9):715-725. doi:10.1016/S2213-8587(19)30084-1 · PMID 31301983H1H5
  163. Nicholls SJ, Pavo I, Bhatt DL, Buse JB, Del Prato S, Kahn SE, et al. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. N Engl J Med. 2025;393(24):2409-2420. doi:10.1056/NEJMoa2505928 · PMID 41406444C5C7D1G2G5H5I1
  164. Nissen SE, Lincoff AM, Brennan D, Ray KK, Mason D, Kastelein JJP, et al. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. N Engl J Med. 2023;388(15):1353-1364. doi:10.1056/NEJMoa2215024 · PMID 36876740C8
  165. Nyström T, Sartipy U, Franzén S, Eliasson B, Gudbjörnsdottir S, Miftaraj M, et al. PCI Versus CABG in Patients With Type 1 Diabetes and Multivessel Disease. J Am Coll Cardiol. 2017;70(12):1441-1451. doi:10.1016/j.jacc.2017.07.744 · PMID 28851544C9
  166. ORIGIN Trial Investigators, Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367(4):319-28. doi:10.1056/NEJMoa1203858 · PMID 22686416C5G2I1
  167. Orozco-Beltrán D, Sánchez E, Garrido A, Quesada JA, Carratalá-Munuera MC, Gil-Guillén VF. Trends in Mortality From Diabetes Mellitus in Spain: 1998-2013. Rev Esp Cardiol (Engl Ed). 2017;70(6):433-443. doi:10.1016/j.rec.2016.09.022 · PMID 27825716H2
  168. Orozco-Beltrán D, Brotons-Cuixart C, Banegas JR, Gil-Guillen VF, Cebrián-Cuenca AM, Martín-Rioboó E, et al. Recomendaciones preventivas vasculares. Actualización PAPPS 2024. Aten Primaria. 2024;56 Suppl 1(Suppl 1):103123. doi:10.1016/j.aprim.2024.103123 · PMID 39613355D1G1H3H5
  169. Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413-1424. doi:10.1056/NEJMoa2022190 · PMID 32865377C7I1
  170. Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2025;392(5):427-437. doi:10.1056/NEJMoa2410027 · PMID 39555826C5C7G2G5I1
  171. Patorno E, Pawar A, Franklin JM, Najafzadeh M, Déruaz-Luyet A, Brodovicz KG, et al. Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care. Circulation. 2019;139(25):2822-2830. doi:10.1161/CIRCULATIONAHA.118.039177 · PMID 30955357G3
  172. Pelliccia A, Sharma S, Gati S, Bäck M, Börjesson M, Caselli S, et al. 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease. Eur Heart J. 2021;42(1):17-96. doi:10.1093/eurheartj/ehaa605 · PMID 32860412C8G1H3
  173. Penno G, Solini A, Orsi E, Bonora E, Fondelli C, Trevisan R, et al. Non-albuminuric renal impairment is a strong predictor of mortality in individuals with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicentre study. Diabetologia. 2018;61(11):2277-2289. doi:10.1007/s00125-018-4691-2 · PMID 30032426G3
  174. Peral Martínez IM, Martínez Pastor A, Gomariz García JJ, Barquilla García A, Martín Sánchez V, Micó Pérez R, et al. Regional differences in the degree of glycaemic diabetes control in Spain and associated factors. IBERICAN study. Endocrinol Diabetes Nutr (Engl Ed). 2023;70(7):448-458. doi:10.1016/j.endien.2023.07.001 · PMID 37468414G3
  175. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380(24):2295-2306. doi:10.1056/NEJMoa1811744 · PMID 30990260C5C10G2I1
  176. Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024;391(2):109-121. doi:10.1056/NEJMoa2403347 · PMID 38785209C5C7C10G2G5I1
  177. Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB. Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition. Diabetes Care. 2015;38(9):1687-93. doi:10.2337/dc15-0843 · PMID 26078479H5
  178. Petrie MC, Udell JA, Anker SD, Harrington J, Jones WS, Mattheus M, et al. Empagliflozin in acute myocardial infarction in patients with and without type 2 diabetes: A pre-specified analysis of the EMPACT-MI trial. Eur J Heart Fail. 2025;27(3):577-588. doi:10.1002/ejhf.3548 · PMID 39725521C5G2
  179. Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med. 2015;373(23):2247-57. doi:10.1056/NEJMoa1509225 · PMID 26630143C5G2H5
  180. Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med. 2021;385(24):2252-2263. doi:10.1056/NEJMoa2110956 · PMID 34449181C5C7C10G2I1
  181. Pop-Busui R, Boulton AJ, Feldman EL, Bril V, Freeman R, Malik RA, et al. Diabetic Neuropathy: A Position Statement by the American Diabetes Association. Diabetes Care. 2017;40(1):136-154. doi:10.2337/dc16-2042 · PMID 27999003H1H5
  182. Praz F, Borger MA, Lanz J, Marin-Cuartas M, Abreu A, Adamo M, et al. 2025 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2025;46(44):4635-4736. doi:10.1093/eurheartj/ehaf194 · PMID 40878295C6
  183. Pujante Alarcón P, Menéndez Torre EL, Morales Sánchez P, Rodríguez Escobedo R, Conde Barreiro S, Rojo Martínez G, et al. Cardiovascular diseases in people with diabetes mellitus in Spain according to the Primary Care Clinical Database (BDCAP) in 2017. Med Clin (Barc). 2022;158(4):153-158. doi:10.1016/j.medcli.2020.12.040 · PMID 33810870G3
  184. Rawshani A, Rawshani A, Franzén S, Eliasson B, Svensson AM, Miftaraj M, et al. Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. N Engl J Med. 2017;376(15):1407-1418. doi:10.1056/NEJMoa1608664 · PMID 28402770G3
  185. Rawshani A, Rawshani A, Franzén S, Sattar N, Eliasson B, Svensson AM, et al. Risk Factors, Mortality, and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2018;379(7):633-644. doi:10.1056/NEJMoa1800256 · PMID 30110583G3
  186. Ray KK, Colhoun HM, Szarek M, Baccara-Dinet M, Bhatt DL, Bittner VA, et al. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7(8):618-628. doi:10.1016/S2213-8587(19)30158-5 · PMID 31272931C8
  187. Real J, Vlacho B, Ortega E, Vallés JA, Mata-Cases M, Castelblanco E, et al. Cardiovascular and mortality benefits of sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus: CVD-Real Catalonia. Cardiovasc Diabetol. 2021;20(1):139. doi:10.1186/s12933-021-01323-5 · PMID 34243779G3
  188. Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966-1986. doi:10.1097/HEP.0000000000000520 · PMID 37363821H5
  189. Rojo-Martínez G, Valdés S, Soriguer F, Vendrell J, Urrutia I, Pérez V, et al. Incidence of diabetes mellitus in Spain as results of the nation-wide cohort Esta dirección de correo electrónico está siendo protegida contra los robots de spam. Necesita tener JavaScript habilitado para poder verlo. study. Sci Rep. 2020;10(1):2765. doi:10.1038/s41598-020-59643-7 · PMID 32066839H2
  190. Romero-Secin AA, Díez-Espino J, Prieto-Díaz MA, Pallares-Carratala V, Barquilla-García A, Micó-Pérez RM, et al. Prevalence, impact and management of hypertension-mediated organ damage in type 2 diabetes patients. Semergen. 2024;50(6):102220. doi:10.1016/j.semerg.2024.102220 · PMID 38554607G3
  191. Romon I, Rey G, Mandereau-Bruno L, Weill A, Jougla E, Eschwège E, et al. The excess mortality related to cardiovascular diseases and cancer among adults pharmacologically treated for diabetes--the 2001-2006 ENTRED cohort. Diabet Med. 2014;31(8):946-53. doi:10.1111/dme.12435 · PMID 24627972G3
  192. Rosenstock J, Kahn SE, Johansen OE, Zinman B, Espeland MA, Woerle HJ, et al. Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial. JAMA. 2019;322(12):1155-1166. doi:10.1001/jama.2019.13772 · PMID 31536101C5C7G2I1
  193. Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, et al. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA. 2019;321(1):69-79. doi:10.1001/jama.2018.18269 · PMID 30418475C5C7G2I1
  194. Rosenstock J, Wysham C, Frías JP, Kaneko S, Lee CJ, Fernández Landó L, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143-155. doi:10.1016/S0140-6736(21)01324-6 · PMID 34186022I1
  195. Rossi A, Masi D, Zilich R, Baccetti F, Baronti W, Falcetta P, et al. Lipid-lowering therapy and LDL target attainment in type 2 diabetes: trends from the Italian Associations of Medical Diabetologists database. Cardiovasc Diabetol. 2025;24(1):94. doi:10.1186/s12933-025-02648-1 · PMID 40022078G3
  196. Rubino F, Cummings DE, Eckel RH, Cohen RV, Wilding JPH, Brown WA, et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol. 2025;13(3):221-262. doi:10.1016/S2213-8587(24)00316-4 · PMID 39824205C7H1H3H5
  197. Russo GT, Corigliano G, Arturi F, Cavallo MG, Bette C, Mannucci E. CAPTURE: A cross-sectional study on the prevalence of cardiovascular disease in adults with type 2 diabetes in Italy. Nutr Metab Cardiovasc Dis. 2022;32(5):1195-1201. doi:10.1016/j.numecd.2022.01.026 · PMID 35260306G3
  198. Rydén L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007;28(1):88-136. doi:10.1093/eurheartj/ehl260 · PMID 17220161G1
  199. Sabatine MS, Leiter LA, Wiviott SD, Giugliano RP, Deedwania P, De Ferrari GM, et al. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5(12):941-950. doi:10.1016/S2213-8587(17)30313-3 · PMID 28927706C8
  200. Sattar N, McMurray J, Borén J, Rawshani A, Omerovic E, Berg N, et al. Twenty Years of Cardiovascular Complications and Risk Factors in Patients With Type 2 Diabetes: A Nationwide Swedish Cohort Study. Circulation. 2023;147(25):1872-1886. doi:10.1161/CIRCULATIONAHA.122.063374 · PMID 37154040G3
  201. Schütt K, Federici M, Verket M, Marx N, Müller-Wieland D. The '10 commandments' for the 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2024;45(15):1298-1300. doi:10.1093/eurheartj/ehad881 · PMID 38195096G1
  202. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317-26. doi:10.1056/NEJMoa1307684 · PMID 23992601C5G2I1
  203. Scirica BM, Braunwald E, Raz I, Cavender MA, Morrow DA, Jarolim P, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014;130(18):1579-88. doi:10.1161/CIRCULATIONAHA.114.010389 · PMID 25189213I1
  204. SCORE2-Diabetes Working Group and the ESC Cardiovascular Risk Collaboration. SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe. Eur Heart J. 2023;44(28):2544-2556. doi:10.1093/eurheartj/ehad260 · PMID 37247330C7H5
  205. SEC Working Group for the 2023 ESC Guidelines on cardiovascular disease in patients with diabetes and SEC Guidelines Committee. Comments on the 2023 ESC guidelines on cardiovascular disease in patients with diabetes. Rev Esp Cardiol (Engl Ed). 2024;77(3):196-200. doi:10.1016/j.rec.2023.11.005 · PMID 38008212G1
  206. Seferović PM, Paulus WJ, Rosano G, Polovina M, Petrie MC, Jhund PS, et al. Diabetic myocardial disorder. A clinical consensus statement of the Heart Failure Association of the ESC and the ESC Working Group on Myocardial & Pericardial Diseases. Eur J Heart Fail. 2024;26(9):1893-1903. doi:10.1002/ejhf.3347 · PMID 38896048H1H5
  207. Sharma A, Pagidipati NJ, Califf RM, McGuire DK, Green JB, Demets D, et al. Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions. Circulation. 2020;141(10):843-862. doi:10.1161/CIRCULATIONAHA.119.041022 · PMID 31992065C5D1H5
  208. Sjöström L, Peltonen M, Jacobson P, Sjöström CD, Karason K, Wedel H, et al. Bariatric surgery and long-term cardiovascular events. JAMA. 2012;307(1):56-65. doi:10.1001/jama.2011.1914 · PMID 22215166H3
  209. Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022;387(12):1089-1098. doi:10.1056/NEJMoa2206286 · PMID 36027570C7I1
  210. Solomon SD, McMurray JJV, Vaduganathan M, Claggett B, Jhund PS, Desai AS, et al. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2024;391(16):1475-1485. doi:10.1056/NEJMoa2407107 · PMID 39225278C5C7D1G2G5I1
  211. Soriguer F, Goday A, Bosch-Comas A, Bordiú E, Calle-Pascual A, Carmena R, et al. Prevalence of diabetes mellitus and impaired glucose regulation in Spain: the Di@bet.es Study. Diabetologia. 2012;55(1):88-93. doi:10.1007/s00125-011-2336-9 · PMID 21987347H2
  212. Spallone V, Ziegler D, Freeman R, Bernardi L, Frontoni S, Pop-Busui R, et al. Cardiovascular autonomic neuropathy in diabetes: clinical impact, assessment, diagnosis, and management. Diabetes Metab Res Rev. 2011;27(7):639-53. doi:10.1002/dmrr.1239 · PMID 21695768H1H5
  213. Steg PG, Bhatt DL, Simon T, Fox K, Mehta SR, Harrington RA, et al. Ticagrelor in Patients with Stable Coronary Disease and Diabetes. N Engl J Med. 2019;381(14):1309-1320. doi:10.1056/NEJMoa1908077 · PMID 31475798C8
  214. Targher G, Dauriz M, Laroche C, Temporelli PL, Hassanein M, Seferovic PM, et al. In-hospital and 1-year mortality associated with diabetes in patients with acute heart failure: results from the ESC-HFA Heart Failure Long-Term Registry. Eur J Heart Fail. 2017;19(1):54-65. doi:10.1002/ejhf.679 · PMID 27790816G3
  215. Tchernof A, Després JP. Pathophysiology of human visceral obesity: an update. Physiol Rev. 2013;93(1):359-404. doi:10.1152/physrev.00033.2011 · PMID 23303913H1H5
  216. The EMPA-KIDNEY Collaborative Group, Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, et al. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023;388(2):117-127. doi:10.1056/NEJMoa2204233 · PMID 36331190C5C7C10G2I1
  217. Thiele H, Akin I, Sandri M, Fuernau G, de Waha S, Meyer-Saraei R, et al. PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock. N Engl J Med. 2017;377(25):2419-2432. doi:10.1056/NEJMoa1710261 · PMID 29083953C9
  218. Thompson A, Fleischmann KE, Smilowitz NR, de Las Fuentes L, Mukherjee D, Aggarwal NR, et al. 2026 AHA/ACC/ACS/ASNC/HRS/SCA/SCCT/SCMR/SVM Guideline for Perioperative Cardiovascular Management for Noncardiac Surgery: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2026;88(13):1543-1643. doi:10.1016/j.jacc.2026.06.017 · PMID 42813718C9
  219. Thuijs DJFM, Kappetein AP, Serruys PW, Mohr FW, Morice MC, Mack MJ, et al. Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial. Lancet. 2019;394(10206):1325-1334. doi:10.1016/S0140-6736(19)31997-X · PMID 31488373C9
  220. Trevisan M, Fu EL, Szummer K, Norhammar A, Lundman P, Wanner C, et al. Glucagon-like peptide-1 receptor agonists and the risk of cardiovascular events in diabetes patients surviving an acute myocardial infarction. Eur Heart J Cardiovasc Pharmacother. 2021;7(2):104-111. doi:10.1093/ehjcvp/pvaa004 · PMID 31999317G3
  221. Tuccinardi D, Zilich R, Ponzani P, Musacchio N, Manicardi V, Rocca A, et al. Real-world prescriptions of GLP-1RAs and SGLT2is in type 2 diabetes prioritise BMI and age over cardiorenal risk: a machine learning-based large cohort analysis. Cardiovasc Diabetol Endocrinol Rep. 2025;11(1):38. doi:10.1186/s40842-025-00251-7 · PMID 41366491G3
  222. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344(18):1343-50. doi:10.1056/NEJM200105033441801 · PMID 11333990C7H3
  223. Ueki K, Sasako T, Okazaki Y, Kato M, Okahata S, Katsuyama H, et al. Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. Lancet Diabetes Endocrinol. 2017;5(12):951-964. doi:10.1016/S2213-8587(17)30327-3 · PMID 29079252C8
  224. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854-65. doi:10.1016/S0140-6736(98)07037-8 · PMID 9742977C5G2I1
  225. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-53. doi:10.1016/S0140-6736(98)07019-6 · PMID 9742976H1
  226. Umpierrez GE, Davis GM, ElSayed NA, Fadini GP, Galindo RJ, Hirsch IB, et al. Hyperglycemic Crises in Adults With Diabetes: A Consensus Report. Diabetes Care. 2024;47(8):1257-1275. doi:10.2337/dci24-0032 · PMID 39052901H5
  227. Ussher JR, Drucker DJ. Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action. Nat Rev Cardiol. 2023;20(7):463-474. doi:10.1038/s41569-023-00849-3 · PMID 36977782H1H5
  228. Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns HJGM, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45(36):3314-3414. doi:10.1093/eurheartj/ehae176 · PMID 39210723B1B4C6D1D3E3G1H3I1
  229. Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018;61(10):2108-2117. doi:10.1007/s00125-018-4670-7 · PMID 30132036H1
  230. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-3337. doi:10.1093/eurheartj/ehab484 · PMID 34458905B4C6C8G1H3I1
  231. von Lewinski D, Kolesnik E, Tripolt NJ, Pferschy PN, Benedikt M, Wallner M, et al. Empagliflozin in acute myocardial infarction: the EMMY trial. Eur Heart J. 2022;43(41):4421-4432. doi:10.1093/eurheartj/ehac494 · PMID 36036746C4C5G2
  232. Voors AA, Angermann CE, Teerlink JR, Collins SP, Kosiborod M, Biegus J, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022;28(3):568-574. doi:10.1038/s41591-021-01659-1 · PMID 35228754I1
  233. Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, et al. 2024 ESC Guidelines for the management of chronic coronary syndromes. Eur Heart J. 2024;45(36):3415-3537. doi:10.1093/eurheartj/ehae177 · PMID 39210710B1B6C2C6C8C9D1D3E3G1H3H4I1
  234. Wang R, Serruys PW, Gao C, Hara H, Takahashi K, Ono M, et al. Ten-year all-cause death after percutaneous or surgical revascularization in diabetic patients with complex coronary artery disease. Eur Heart J. 2021;43(1):56-67. doi:10.1093/eurheartj/ehab441 · PMID 34405232C9
  235. Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016;375(4):323-34. doi:10.1056/NEJMoa1515920 · PMID 27299675C5G2
  236. Wheeler DC, Pantalone KM, Guo L, Desai NR, Correa-Rotter R, Nicholas SB, et al. Dosing, treatment patterns and safety of finerenone use in routine care: an interim analysis of the prospective, real-world and observational FINE-REAL study. Clin Kidney J. 2025;18(11):sfaf305. doi:10.1093/ckj/sfaf305 · PMID 41220896G3
  237. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327-35. doi:10.1056/NEJMoa1305889 · PMID 23992602C5G2I1
  238. Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. doi:10.1111/dom.14725 · PMID 35441470H3
  239. Wing RR, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34(7):1481-6. doi:10.2337/dc10-2415 · PMID 21593294H3
  240. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380(4):347-357. doi:10.1056/NEJMoa1812389 · PMID 30415602C5C7G2I1
  241. Writing Committee Members, Ndumele CE, Rodriguez F, Dixon DL, Khan SS, Mukherjee D, et al. 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026;154(4):e50-e158. doi:10.1161/CIR.0000000000001453 · PMID 42263157G1
  242. Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015;385(9982):2067-76. doi:10.1016/S0140-6736(14)62225-X · PMID 25765696C5G2I1
  243. Zareini B, Blanche P, D'Souza M, Elmegaard Malik M, Nørgaard CH, Selmer C, et al. Type 2 Diabetes Mellitus and Impact of Heart Failure on Prognosis Compared to Other Cardiovascular Diseases: A Nationwide Study. Circ Cardiovasc Qual Outcomes. 2020;13(7):e006260. doi:10.1161/CIRCOUTCOMES.119.006260 · PMID 32571092G3
  244. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-28. doi:10.1056/NEJMoa1504720 · PMID 26378978C5C7G2H5I1
  245. Zoungas S, Chalmers J, Neal B, Billot L, Li Q, Hirakawa Y, et al. Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med. 2014;371(15):1392-406. doi:10.1056/NEJMoa1407963 · PMID 25234206I1
  246. Zoungas S, Arima H, Gerstein HC, Holman RR, Woodward M, Reaven P, et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol. 2017;5(6):431-437. doi:10.1016/S2213-8587(17)30104-3 · PMID 28365411C7H1H5
  247. Álvarez-Guisasola F, Quesada JA, López-Pineda A, García RN, Carratalá-Munuera C, Gil-Guillén VF, et al. Multicausal analysis of mortality due to diabetes mellitus in Spain, 2016-2018. Prim Care Diabetes. 2024;18(2):138-145. doi:10.1016/j.pcd.2024.01.013 · PMID 38326176H2

Otros documentos con DOI (3)

  1. Artola Menéndez S, García Soidán FJ. Actualización del algoritmo de tratamiento de la diabetes mellitus tipo 2 redGDPS 2026. Diabetes práctica. 2026. doi:10.52102/diabet/pract.2025.4.art1G1
  2. García Soidán FJ. Algoritmo de tratamiento de la diabetes mellitus tipo 2. RedGDPS 2023. diabetpract. 2023;14(2):43-52. doi:10.52102/diabet/pract.2023.2.art2G1
  3. Mediavilla Bravo JJ. Algoritmo de tratamiento de la enfermedad renal crónica en las personas con diabetes mellitus tipo 2 redGDPS 2022. diabetpract. 2023;14(S2):3-4. doi:10.52102/diabet/pract.renal.art1G1

Fichas técnicas (CIMA, AEMPS) (46)

  1. Ficha técnica de acarbosa. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 14/11/2026. CIMA, registro 70451C3
  2. Ficha técnica de alogliptina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 14/11/2026. CIMA, registro 113844021C3C4I1
  3. Ficha técnica de canagliflozina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 14/11/2026. CIMA, registro 113884002C3C10I1
  4. Ficha técnica de dapagliflozina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 14/11/2026. CIMA, registro 112795007C1C3C4C7C10D4I1
  5. Ficha técnica de dapagliflozina y metformina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 14/11/2026. CIMA, registro 113900009I1
  6. Ficha técnica de dulaglutida. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 14/11/2026. CIMA, registro 114956002C3C4D4I1
  7. Ficha técnica de empagliflozina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 14/11/2026. CIMA, registro 114930014C1C3C4C7C10D4I1
  8. Ficha técnica de empagliflozina y linagliptina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 14/11/2026. CIMA, registro 1161146005I1
  9. Ficha técnica de empagliflozina y metformina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 14/11/2026. CIMA, registro 1151003032I1
  10. Ficha técnica de enalapril. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 14/11/2026. CIMA, registro 57789C10
  11. Ficha técnica de ertugliflozina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 14/11/2026. CIMA, registro 1181267002C3I1
  12. Ficha técnica de ertugliflozina y metformina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 14/11/2026. CIMA, registro 1181265011I1
  13. Ficha técnica de finerenona. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 14/11/2026. CIMA, registro 1211616002C1C3C4C7C10D4I1
  14. Ficha técnica de finerenona. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 14/11/2026. CIMA, registro 1211616007C3
  15. Ficha técnica de finerenona. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 14/11/2026. CIMA, registro 1211616012C3
  16. Ficha técnica de glibenclamida. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 14/11/2026. CIMA, registro 50337C3
  17. Ficha técnica de gliclazida. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 14/11/2026. CIMA, registro 71738C1C3C4D4I1
  18. Ficha técnica de glimepirida. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 14/11/2026. CIMA, registro 61406C3C4I1
  19. Ficha técnica de glipizida. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 14/11/2026. CIMA, registro 51293C3
  20. Ficha técnica de insulina asparta. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 14/11/2026. CIMA, registro 99119009C3D4
  21. Ficha técnica de insulina degludec. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 14/11/2026. CIMA, registro 112807004C3I1
  22. Ficha técnica de insulina glargina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 14/11/2026. CIMA, registro 00134033C3C4D4I1
  23. Ficha técnica de insulina glargina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 14/11/2026. CIMA, registro 100133034C3I1
  24. Ficha técnica de insulina glulisina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 14/11/2026. CIMA, registro 04285032C3
  25. Ficha técnica de insulina lispro. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 14/11/2026. CIMA, registro 96007031C3
  26. Ficha técnica de irbesartán. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 14/11/2026. CIMA, registro 97046022C10
  27. Ficha técnica de linagliptina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 14/11/2026. CIMA, registro 11707004C3C4C7I1
  28. Ficha técnica de liraglutida. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 14/11/2026. CIMA, registro 09529002D4
  29. Ficha técnica de liraglutida. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 14/11/2026. CIMA, registro 115992002C3
  30. Ficha técnica de liraglutida. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 14/11/2026. CIMA, registro 89788C3C4I1
  31. Ficha técnica de losartán. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 14/11/2026. CIMA, registro 64971C10
  32. Ficha técnica de metformina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 14/11/2026. CIMA, registro 55211C3C7D4I1
  33. Ficha técnica de metformina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 14/11/2026. CIMA, registro 68167C1C3C4H3
  34. Ficha técnica de metformina y canagliflozina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 14/11/2026. CIMA, registro 114918011I1
  35. Ficha técnica de pioglitazona. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 14/11/2026. CIMA, registro 00150004C1C3C4I1
  36. Ficha técnica de repaglinida. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 14/11/2026. CIMA, registro 98076012C3
  37. Ficha técnica de saxagliptina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 14/11/2026. CIMA, registro 09545006C3C4I1
  38. Ficha técnica de semaglutida. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 14/11/2026. CIMA, registro 117251002C1C3C4C7C10D4I1
  39. Ficha técnica de semaglutida. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 14/11/2026. CIMA, registro 1201430017C3C4C7D4I1
  40. Ficha técnica de semaglutida. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 14/11/2026. CIMA, registro 1211608010C3H3
  41. Ficha técnica de semaglutida. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 14/11/2026. CIMA, registro 1211608023C3
  42. Ficha técnica de semaglutida. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 14/11/2026. CIMA, registro 1211608025C3
  43. Ficha técnica de sitagliptina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 14/11/2026. CIMA, registro 07383014C3C4I1
  44. Ficha técnica de tirzepatida. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 14/11/2026. CIMA, registro 1221685049C1C3C4C7D4I1
  45. Ficha técnica de tirzepatida. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 14/11/2026. CIMA, registro 1221685055H3
  46. Ficha técnica de vildagliptina. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Centro de Información online de Medicamentos (CIMA). Consultada el 14/11/2026. CIMA, registro 07414003C3C4I1
La lista se hace sola con lo que citan las páginas de este ESPACIO (PubMed por el PMID; el DOI, en PubMed o en Crossref; las fichas técnicas, en CIMA; los estudios en marcha, en ClinicalTrials.gov) y se rehace cada vez que se actualiza el ESPACIO; seis autores y «et al.», como pide el estilo Vancouver.

ESPACIO formativo de CardioTeca.com sobre diabetes. Contenidos elaborados con independencia editorial y dirigidos a profesionales sanitarios. Los fármacos se nombran por su denominación común internacional. Edita y revisa el Comité Editorial de CardioTeca. Última actualización: .

Comité científico · Independencia editorial · Preguntas sobre el ESPACIO

Cuenta gratuitapara profesionales sanitarios

Únete a la comunidad CardioTeca

Ya somos más de 27.000 profesionales. Crear tu cuenta te lleva un par de minutos.

Ejemplo de página profesional en CardioTeca
  • Accede sin límites a todos los contenidos y servicios de CardioTeca.
  • Tu página profesional, con tu foto, tus servicios, currículum, web y pedir cita.
  • Medicamentos, guías interactivas y calculadoras para el día a día.
  • Recibe en tu mail casos clínicos, comentarios de expertos y todas las novedades.
Ejemplo de página profesional en CardioTeca
Crear mi cuenta gratis ¿Ya tienes cuenta? Inicia sesión

Actualidad

Formación

CardioTeca

Legal

La información que figura en CardioTeca.com está dirigida exclusivamente al profesional sanitario facultado para prescribir o dispensar medicamentos, por lo que se requiere una formación especializada para su correcta interpretación. El acceso a algunas secciones se realiza mediante contraseña, y sólo está disponible para profesionales sanitarios. Aunque el sitio web CardioTeca.com está dirigido a profesionales de la salud, la información médica visible en su área pública es de libre acceso. Por ello, queremos aclarar que el uso de estos contenidos por parte de la población no reemplaza en ningún momento la relación entre el médico y el paciente. Para obtener información específica sobre un caso concreto consulte siempre a su médico. En CardioTeca.com empleamos inteligencia artificial como herramienta de apoyo editorial, bajo supervisión de nuestro equipo médico.